A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 [RNA-loaded dendritic cell cancer vaccine] as a Vaccine in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma.

Trial Profile

A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 [RNA-loaded dendritic cell cancer vaccine] as a Vaccine in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jan 2012

At a glance

  • Drugs Cancer vaccine (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2012 Actual patient number is 26 according to ClinicalTrials.gov.
    • 22 Dec 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top